SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Synergy Pharmaceuticals Initiates Dosing of Healthy Volunteers in Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Ulcerative Colitis